The study, which was put together by Finland's Radiation and Nuclear Safety Authority, suggests that people who used cellphones longer than 10 years were 40 percent more likely to develop gliomas (a nervous system tumor) on the side of the head where the cellphone's radiation would enter the head.
The next big trial results for Erbitux are expected next spring, when ImClone is likely to release results of a big phase-3 trial combining Erbitux with radiation in treating head and neck cancer.
MediPharma has two drugs derived from Chinese herbs in midstage clinical trials in the U.S., one to improve the potency of radiation therapy on head and neck cancer and the other to treat Crohn's disease, an inflammation of the digestive tract.